FDA Eases REMS and Monitoring Rules to Improve CAR-T Access

Published on LinkedIn via Spencer Knight

The FDA has updated CAR-T therapy regulations for BMS’ Abecma and Breyanzi, removing REMS requirements and reducing monitoring burdens. These changes are expected to improve patient access, especially in underserved regions where families previously had to travel long distances to certified treatment centers. With lower post-treatment proximity requirements and shorter driving restrictions, CAR-T may soon become more accessible in community hospital settings across the U.S.

Read the full article on LinkedIn:

👉 FDA eases CAR-T restrictions to expand access for patients

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.